Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GNFT 
Genfit S.A. (GNFT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/13/2025: GNFT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.4
1 Year Target Price $7.4
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -47.35% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 223.06M USD | Price to earnings Ratio - | 1Y Target Price 7.4 |
Price to earnings Ratio - | 1Y Target Price 7.4 | ||
Volume (30-day avg) 1 | Beta 1.33 | 52 Weeks Range 2.55 - 6.42 | Updated Date 10/12/2025 |
52 Weeks Range 2.55 - 6.42 | Updated Date 10/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.91 |
Earnings Date
Report Date 2025-09-22 | When After Market | Estimate 0.1141 | Actual -0.2 |
Profitability
Profit Margin -85.89% | Operating Margin (TTM) 0.18% |
Management Effectiveness
Return on Assets (TTM) -8.54% | Return on Equity (TTM) -51.74% |
Valuation
Trailing PE - | Forward PE 7.27 | Enterprise Value 87777048 | Price to Sales(TTM) 4.94 |
Enterprise Value 87777048 | Price to Sales(TTM) 4.94 | ||
Enterprise Value to Revenue 1.8 | Enterprise Value to EBITDA 20.05 | Shares Outstanding 50002890 | Shares Floating 43779467 |
Shares Outstanding 50002890 | Shares Floating 43779467 | ||
Percent Insiders - | Percent Institutions 0.16 |
Upturn AI SWOT
Genfit S.A.
Company Overview
History and Background
Genfit S.A. is a biopharmaceutical company founded in 1999, initially focused on liver diseases. It has evolved to specialize in metabolic and liver diseases, with a focus on developing therapeutic solutions for patients with high unmet medical needs.
Core Business Areas
- Therapeutic Development: Research and development of drug candidates for metabolic and liver diseases.
- Diagnostics: Development of diagnostic solutions to identify patients at risk.
- Licensing and Partnerships: Out-licensing and partnering with other pharmaceutical companies.
Leadership and Structure
Genfit S.A. is led by a board of directors and an executive management team, comprising professionals with expertise in drug development, finance, and commercialization. Details can be found on the company's investor relations page.
Top Products and Market Share
Key Offerings
- Elafibranor (GFT505): A PPAR alpha/delta agonist that was developed for the treatment of Non-Alcoholic Steatohepatitis (NASH). While its development was discontinued, it represents a significant part of the company's research history. Competitors in the NASH space include Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX).
- NIS4u00ae technology: A proprietary, non-invasive diagnostic technology for the stratification of patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and NASH. Competitors in this area include companies developing similar diagnostic solutions.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and subject to regulatory scrutiny. The specific market for metabolic and liver diseases, particularly NASH, is large and growing, driven by increasing prevalence of obesity and related conditions.
Positioning
Genfit is positioning itself as a specialist in metabolic and liver diseases, focusing on both therapeutic and diagnostic solutions. They try to differentiate themselves with innovative approaches and proprietary technologies.
Total Addressable Market (TAM)
The global NASH market is expected to reach tens of billions of dollars in the coming years. Genfit's position depends on their NASH pipeline and diagnosis business, and successful execution of these products.
Upturn SWOT Analysis
Strengths
- Specialized focus on metabolic and liver diseases
- Proprietary diagnostic technology (NIS4u00ae)
- Experienced management team
Weaknesses
- High R&D expenses with no currently approved drug
- Dependence on successful development and commercialization of new products
- Past setback in NASH program with Elafibranor
Opportunities
- Growing prevalence of NASH and other metabolic diseases
- Potential for strategic partnerships and collaborations
- Expansion of diagnostic business
Threats
- Regulatory hurdles and approval timelines
- Competition from larger pharmaceutical companies
- Clinical trial failures and unexpected adverse events
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- GILD
- ICPT
Competitive Landscape
Genfit faces competition from both large pharmaceutical companies and smaller biotech firms. Success depends on scientific innovation and efficient execution.
Major Acquisitions
Versantis AG
- Year: 2022
- Acquisition Price (USD millions): 32
- Strategic Rationale: Expanded pipeline in liver diseases, specifically for acute-on-chronic liver failure (ACLF).
Growth Trajectory and Initiatives
Historical Growth: Genfit's historical growth has been driven by advances in its R&D pipeline and strategic partnerships.
Future Projections: Future growth depends on the successful development and commercialization of its drug candidates and diagnostic solutions. Analyst estimates would provide specific projections, which are not available here.
Recent Initiatives: Recent initiatives include advancing its diagnostic technologies and exploring strategic partnerships.
Summary
Genfit is a specialized biopharmaceutical company focused on liver and metabolic diseases. Despite past setbacks in NASH, they are actively working on new drug programs and diagnostic technologies. Success depends on effective execution of their pipeline strategy and strategic partnerships. Potential investors need to consider the company's high R&D spending with currently no commercialized product and also the competitive landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Genfit S.A. Investor Relations
- Company press releases
- Third-party market research reports
- SEC Filings
- Yahoo Finance
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genfit S.A.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-03-27 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 188 | Website https://www.genfit.com |
Full time employees 188 | Website https://www.genfit.com | ||
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.